News
ORIGINAL: Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
2021-03-18 08:30 ET - News Release
SAN FRANCISCO and TORONTO, March 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that Robert Farrell, J.D., the Company’s President and CEO has been appointed Chairman of the Company’s board of directors (the “Board of Directors”), effective immediately.
The Company also announced the resignations of current independent board members Mr. Robin (“Rob”) Hutchison and Ronald Erickson, J.D., effective immediately. The resignations of Mr. Hutchison and Mr. Erickson follows the recent appointment of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors. Prof. Cuzzocrea is an independent board member, and is an acknowledged expert in the science of nitric oxide therapy.
"I want to extend my gratitude to Rob Hutchison and Ron Erickson for their distinguished service and contributions to our Board of Directors,” stated Mr. Farrell. “Both Rob and Ron have been integral members of our Board of Directors, and we wish them all the best going forward.”
“We are assembling a world-class team of experts in the science and clinical use of nitric oxide, at management, advisory and board levels within the Company,” stated Farrell. “We recently announced the addition of Prof. Salvatore Cuzzocrea to our board of directors, and the addition of Dr. Garry Southan to our Scientific Advisory Board. Prof. Cuzzocrea and Dr. Southan are each world-renowned experts in the science of nitric oxide. Our proprietary new drug, R-107, is a liquid, nitric oxide releasing molecule that could transform nitric oxide therapy from a difficult to use inhalational therapy to a pharmaceutical that can be administered orally by capsule or by injection. R-107 is a platform technology that is designed to unleash the potential of nitric oxide as a practical out-patient therapy for many diseases and disorders. With R-107, we will position Claritas as the world’s leader in nitric oxide pharmacology.”
About Claritas Pharmaceuticals
Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives.